Llusern is pleased to announce that three abstracts will be presented at the International Continence Society congress in Maastricht, 6-9 October 2026 focusing on the application of the Lodestar UTI testing system.
Each abstract considers a different patient setting and demonstrates ways in which Lodestar can fundamentally change the patient treatment pathway.
1. Abstract discussing the feasibility of using Lodestar DX to support assessment of UTI symptoms in care home residents has been accepted for presentation by the committee at ICS 2026.
https://www.ics.org/2026/abstract/464
2. Abstract evaluating Lodestar DX against standard culture and dipstick in an acute outpatient clinic.
https://www.ics.org/2026/abstract/828</a
3. Abstract evaluating Lodestar DX against standard culture and dipstick for pre-operative screening.
https://www.ics.org/2026/abstract/189
